Company news
4D Molecular Therapeutics, Inc. news in 2021
4D Molecular Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.
4D Molecular Therapeutics Reports Financial Results for the Third Quarter of 2021 and Provides Operational Highlights
November 9, 2021
4D Molecular Therapeutics Announces Pricing of Public Offering of Common Stock
October 27, 2021
4D Molecular Therapeutics Reports Interim Results from the 4D-310 Phase 1/2 Clinical Trial in Patients with Fabry Disease and Provides Clinical Data Update from the 4D-110 Phase 1/2 Clinical Trial in Patients with Choroideremia
October 24, 2021
4D Molecular Therapeutics Presents Interim Results from the Ongoing 4D-125 Phase 1/2 Clinical Trial in Patients with Advanced X-linked Retinitis Pigmentosa at the ASRS Annual Meeting
October 9, 2021
4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-710, an A101 Vector-based, Aerosol-delivered Gene Therapy for the Treatment of Cystic Fibrosis Lung Disease
October 5, 2021
4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150, a Dual-Transgene Intravitreal Gene Therapy for Patients with wet AMD
October 5, 2021
4D Molecular Therapeutics Announces Late-Breaking Presentation of 4D-125 Clinical Data at the Upcoming ASRS Annual Meeting
September 23, 2021
4D Molecular Therapeutics Reports Financial Results for the Second Quarter of 2021 and Provides Operational Highlights
August 11, 2021
4D Molecular Therapeutics Announces Rare Disease Ophthalmology Product Candidate Portfolio Update, Including Initial Clinical Safety and Tolerability Data for 4D-110 for Choroideremia and 4D-125 for XLRP, and Termination of Roche Collaboration and Lic...
June 23, 2021
4D Molecular Therapeutics Appoints Carolyne Zimmermann as Chief Business Officer
June 6, 2021
4D Molecular Therapeutics Reports Financial Results for the First Quarter of 2021 and Provides Operational Highlights
May 12, 2021
4D Molecular Therapeutics Presents Non-Human Primate Preclinical Data at ASGCT on the 4D-150 Product Candidate for wet AMD and DME
May 11, 2021
4D Molecular Therapeutics Announces Collaboration on Leading Machine Learning Technology and Expertise from U.C. Berkeley to Expand Therapeutic Vector Evolution Platform
May 3, 2021
4D Molecular Therapeutics Announces Preclinical Data Presentations at ASGCT and ATS Annual Meetings on Three Wholly-Owned Product Candidates from Non-Human Primate Studies
April 26, 2021
4D Molecular Therapeutics Reports Financial Results for the Year Ended December 31, 2020 and Provides Operational Highlights
March 24, 2021
4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-310 for the Treatment of Fabry Disease
March 8, 2021
Decks in 2021
- Technical Presentation (2021)
Technical · 9 slides · 2021
- Technical Presentation (2021)
Technical · 17 slides · 2021
- ASGCT 2021
Conference · 14 slides · 2021